Cediranib plus olaparib significantly increases PFS in recurrent ovarian cancer
31 May 2014
Cediranib plus olaparib significantly increases PFS in recurrent ovarian cancer
Ibrutinib significantly delays disease progression and extends survival in resistant or relapsed CLL
Emerging pathways in immunotherapy
Checkpoint blockade: a concept or already a reality?
Cancer evasion of the immune system: the fundamentals
New rules for clinical trials
ecancermedicalscience Editor's Choice for May 2014
Myeloma genomics and Immuno-oncology
Novel targets and immune based therapy in myeloma
Upcoming trends in myeloma therapy
Recent advances in mantle cell lymphoma: Expert panel discussion
Lecture: PSA Screening - Where East meets West